Stockreport

Moderna's Covid-19 vaccine meets primary efficacy endpoint in Phase III trial [Yahoo! Finance]

Moderna, Inc.  (MRNA) 
Last moderna, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: marinabio.com/investor-relations
PDF The vaccine demonstrated non-inferior efficacy against Covid-19 compared to Spikevax (mRNA-1273). Notably, the trial observed higher efficacy in adults aged 18 years [Read more]